Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a ...
Amgen (AMGN) stock drops after a phase 3 trial failure for a heart drug from Novartis (NVS) and Ionis Pharma (IONS). BMO ...
Pelacarsen lowered Lp(a) levels in more than 8,000 patients but did not reduce the risk of heart attacks, strokes, or ...
Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite ...
Amgen ( AMGN) dropped just over 10% on Tuesday after a late-stage cardiovascular trial failure at Novartis raised concerns ...
Sept 8 (Reuters) - Amgen's targeted immunotherapy, Imdelltra, combined with AstraZeneca's cancer drug Imfinzi, significantly ...
Amgen (NASDAQ:AMGN) shares fell 4.7% to $416.88 in premarket trading as investors assessed the implications of a Phase III trial result from Novartis involving an experimental Lp (a)-lowering ...
Novartis shares dropped Tuesday after the company reported disappointing results from a clinical trial. U.S.-listed shares of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results